Scholars Central

Conference abstractPublished 12 Nov 2013

CAPA and risk management

Authors: Rucha Majmundar Mehta

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The pharmaceutical company should have a system for implementing corrective actions and preventive actions resulting from the; investigation of complaints, Product rejections, Non- conformances, Recalls, deviations, Audits, Regulatory inspections and findings, and Trends from process performance and product quality monitoring. A structured approach to the investigation process should be used with the objective of determining the root cause. The level of effort, formality, and documentation of the investigation should be commensurate with the level of risk, In line with ICH Q9 ?Quality Risk Management?. CAPA methodology should result in product and process improvements and enhanced product and process understanding. Corrective Action: Corrective action is aiming to correct an existing non-conformity and to avoid reoccurrence of the same nonconformity. Corrective action may arise, from manufacturing deviations, OOS investigations, complaints, audit findings, recalls. A systematic investigation should be performed to determine the reason(s) for the non-conformities and to agree upon appropriate corrective action. All Agreed corrective actions should be closely followed-up and monitored till completion. Management should be notified about the costs and impact of failure including the respective corrective actions. Preventive Action: Preventive action should be aiming to avoid the initial occurrence of non-conformity by proactively implementing improvements. Preventive action may result from trending of in process data, of analytical data, of audit findings, Trending of root causes for non-conformities or complaints, From product quality reviews (annual product reviews), Quality risk analyses, etc. Similar to corrective actions, All Agreed Preventive Actions should be closely followed-up and monitored till their completion. Effectiveness of preventive actions should be reviewed regularly, as part of the product quality review (annual product review). Effective CAPA Process, CAPA Challenges & CAPA Management Software are the key factors

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Developing Drugs.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Developing Drugs
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Rucha Majmundar Mehta”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels